Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: Evaluation of risk factors for liver enzyme elevation

HIV Medicine

Volumn 5, Issue 5, 2004, Pages 334-343

  Meraviglia, Paola ^a   Schiavini, M ^a   Castagna, A ^b   Vigano P ^c   Bini, T ^a   Landonio, S ^a   Danise, A ^b   Moioli, M C ^d   Angeli, E ^a   Bongiovanni, M ^a   Hasson, H ^b   Duca, P ^b   Cargnel, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Hospital of Legnano   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Liver enzyme elevation; Lopinavir ritonavir; Viral hepatitis coinfection

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPRENAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; GAMMA GLUTAMYLTRANSFERASE; INDINAVIR; LAMIVUDINE; LIPID; LIVER ENZYME; LOPINAVIR; NELFINAVIR; NEVIRAPINE; OMEGA 3 FATTY ACID; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; AGE; AGED; ARTICLE; BIOCHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG SURVEILLANCE PROGRAM; ECHOGRAPHY; FEMALE; GENDER; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNOLOGY; INCIDENCE; ITALY; LIVER TOXICITY; LYMPHOCYTE COUNT; MALE; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS B; HIV INFECTIONS; HUMANS; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINONES; RISK FACTORS; RITONAVIR; STATISTICS, NONPARAMETRIC;

EID: 4644341941     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00232.x     Document Type: Article

References (33)

1. Savès M, Vandentorren S, Daucourt V et al. Severe hepatic cytolisis incidence and risk factors in patients treated by antiretroviral combination. Aquitaine Cohort, France, 1996-98. AIDS 1999; 13: 115.
2. Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy. Role of hepatitis C and B infections. Hepatology 2002; 35: 182-189.
3. Rancinan C, Neau D, Savès M et al. Is hepatitis C co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 2002; 16: 1357-1362.
4. den Brinker M, Wit FW, Wertheim-van Dillen PM et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 2895-2902.
5. Martinez E, Blanco JL, Arnaiz J et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268.
6. Bonfanti P, Landonio S, Ricci E et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquit Immune Defic Syndr 2001; 27: 316-318.
7. Sukkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretrovirad therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J Am Med Assoc 2000; 283: 74-80.
8. Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002; 34: 1259-1263.
9. Orenstein R, Tsogas N. Looking beyond highly active antiretroviral therapy: drug-related hepatoxicity in patients with human immunodeficiency virus infection. Pharmacotherapy 2002; 22: 1468-1478.
10. Bonnet F, Lawson-Ayayi S, Thiebaut R, Ramanampamionjy R, Lacoste D, Bernard N. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-99. Clin Infect Dis 2002; 35: 1231-1237.
11. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretrovirat combination therapy. AIDS 1998; 12: 116-117.
12. John M, Flexman J, French MAH. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with protease inhibitors: an immune restoration disease? AIDS 1998; 12: 2289-2293.
13. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: the end of opportunism? J Am Med Assoc 1998; 280: 72-77.
14. Kaletra (Lopinavir/Ritonavir) Product Monograph. Abbott Laboratories, 2001: 55-56.
15. Arribas J, Barra C, Gonzales-Lahoz J et al. Treatment of HIV + subjects co-infected with hepatitis B or C: safety and efficacy comparison of ABT-378/ritonavir vs. Nelfinavir from a phase III blinded randomized clinical trial. 5th International Congress on Drug Therapy in HIV Infection Glasgow, October 2000 [Abstract P369].
16. Bernstein B, King M, Cernohous P, Moseley J, Sun E. Treatment of HIV subjects co-infected with hepatitis B or C: week 60 safety and efficacy comparison of LPV/r vs. Nelfinavir from a phase III blinded randomized clinical trial. 8th European Conference on Clinical Aspects and Treatment of HIV Infection. Athens, October 2001 [Abstract P228].
17. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
18. Ishak K. Pathologic features of chronic hepatitis. A review and update. Am J Clin Pathol 2000; 113: 40-55.
19. Bonfanti P, Valsecchi L, Parazzini F et al. Incidence of adverse reaction in HIV patients treated with protease inhibitors: a cohort study. J Acquir Immune Defic Syndr 2000; 23: 236-244.
20. Gisolf EH, Dreezen C, Danner SA, Well JL, Weverling GJ. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis 2000; 31: 1234-1239.
21. Monforte A, Burgarini R, Pezzotti P et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquit Immune Defic Syndr 2001; 28: 114-123.
22. Soriano V, Kirck O, Antunes F et al. The influence of hepatitis C on the prognosis of HIV-infected persons: the EuroSIDA study XIIIth International AIDS Conference. Durban, July 2000 [Abstract Th.0rB655].
23. Thomas D. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002; 36: S201-S209.
24. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV infected patients. Prevalence and prognostic value. J Hepatol 1997; 27: 18-24.
25. Marusawa H, Uemoto S, Hijikata M et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31: 488-495.
26. Benhamou Y, Di Martino V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected eatients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283-247.
27. Nunez M, Rios P, Martin-Carbonero L, Perez-Olmeda M, Gonzales Lahoz J, Soriano V. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30: 65-68.
28. Khalili M, Behm BW. Hepatitis C in the setting of HIV co-infection. Microbes Infect 2002; 4: 1247-1251.
29. Martin-Carbonero L, Nunez M, Rios P, Perez-Olmeda M, Gonzales-lahoz J, Soriano V. Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. AIDS 2002; 16: 1423-1425.
30. Chisari FV, Ferrari C. Viral hepatitis. In: Nathanson N, ed. Viral Pathogenesis. Philadelphia, Lippincott-Raven Publishers, 1997: 745-778.
31. Minutello MA, Pileri P, Unutmaz D et al. Compartmentalization of T-lymphocyle to the site of disease: intrahepatic CD4 + T-cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis. J Exp Med 1993; 178: 17-25.
32. Arribas J, Pulido F, Peng JZ et al. Evaluation of the multiple-dose pharmacokinetics of lopinavir/ritonavir in HIV and HCV co-infected subjects with mild or moderate hepatic insufficiency. 9th European Aids Conference Warsaw, 25-29 October 2003 [Abstract F2/6].
33. Gonzales de Requena D, Nunez M, Gonzales-Lahoz J, Soriano V. Liver toxicity of lopinavir/ritonavir containing regiments in HIV infected patients with or without hepatitis C virus (HCV) co-infection. 9th European Aids Conference Warsaw, 25-29 October 2003 [Abstract 9.6/1].